Document Detail


Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
MedLine Citation:
PMID:  17944738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Rectally administered mesalazine (mesalamine; 5-aminosalicylic acid) is the first-line therapy for treatment of distal ulcerative colitis. Recently, a high-volume 5-aminosalicylic acid foam has been shown to be as effective and safe as standard 5-aminosalicylic acid enema. AIM: To study the efficacy and safety of a low-volume vs. a high-volume 5-aminosalicylic acid foam. METHODS: In this investigator-blinded study, patients with active distal ulcerative colitis [Clinical Activity Index (CAI) > 4, Endoscopic Index > or = 4] were randomized to receive 2 x 1 g/30 mL low-volume (n = 163) or 2 x 1 g/60 mL high-volume 5-aminosalicylic acid foam (n = 167) for 42 days. Primary end point was clinical remission (CAI < or = 4) at the final/withdrawal visit (per-protocol). RESULTS: 330 patients were evaluable for efficacy and safety by intention-to-treat, 290 for per-protocol analysis. Clinical remission rates at week 6 (per-protocol) were 77% on low-volume foam vs. 77% on high-volume foam (P = 0.00002 for non-inferiority). The low-volume foam was associated with a lower frequency of severe discomfort, pain and retention problems. CONCLUSIONS: Low-volume 5-aminosalicylic acid foam is as effective and safe as a high-volume 5-aminosalicylic acid foam in the treatment of active distal ulcerative colitis, but offers compliance advantages compared to the high-volume preparation.
Authors:
R Eliakim; Z Tulassay; L Kupcinskas; K Adamonis; J Pokrotnieks; S Bar-Meir; A Lavy; R Mueller; R Greinwald; I Chermesh; V Gross;
Related Documents :
3338638 - Subepithelial tissue ph of rat gastric mucosa exposed to luminal acid, barrier breaking...
3835428 - Stress and ulceration: medico-legal aspects.
8772508 - Mechanisms behind changes in gastric acid and bicarbonate outputs during the human inte...
2221078 - Lipid binding to gastric mucin: protective effect against oxygen radicals.
1841188 - Contribution of temperature gradient to aggregation of thermal heterocopolymers of amin...
16402248 - The effects of propionibacterium acidipropionici and lactobacillus plantarum, applied a...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  26     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-19     Completed Date:  2008-03-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1237-49     Citation Subset:  IM    
Affiliation:
Gastroenterology Department, Rambam Medical Center, Haifa, Israel. r_eliakim@rambam.health.gov.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Rectal
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*,  adverse effects,  therapeutic use
Colitis, Ulcerative / drug therapy*
Female
Humans
Male
Mesalamine / administration & dosage*,  adverse effects,  therapeutic use
Middle Aged
Single-Blind Method
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 89-57-6/Mesalamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A prospective comparative study of five measures of gluten-free diet adherence in adults with coelia...
Next Document:  Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin...